
NYSEHealthcareDrug Manufacturers - General
Latest quote
$27.72
+$0.07 · +0.25%
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Previous close
$27.72
+$0.07 · +0.25%
Regular session · ET · Market data may be delayed.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Day range
Current $27.72
52-week range
Current $27.72
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
78
Undervalued
Sentiment
48
Mixed
Risk
18
Low Risk
Momentum
36
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Day range
Current $27.72
52-week range
Current $27.72
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 62.58B USD | 63.63B USD | 59.55B USD | 100.33B USD | 81.29B USD |
| Cost of goods sold | 18.57B USD | 21.78B USD | 29.21B USD | 38.24B USD | 34.41B USD |
| Gross profit | 44.01B USD | 41.85B USD | 30.34B USD | 62.09B USD | 46.88B USD |
| Research and development | 11.98B USD | 10.74B USD | 10.58B USD | 11.43B USD | 13.83B USD |
| Selling, general, and administrative | 13.35B USD | 14.73B USD | 14.47B USD | 13.12B USD | 12.25B USD |
| Operating expenses | 28.58B USD | 25.36B USD | 25.05B USD | 24.54B USD | 26.08B USD |
| Interest income | 603M USD | 545M USD | 1.62B USD | 251M USD | 36M USD |
| Interest expense | 2.67B USD | 3.09B USD | 2.21B USD | 1.24B USD | 1.29B USD |
| Depreciation and amortization | 4.91B USD | 7.01B USD | 6.29B USD | 5.06B USD | 5.19B USD |
| Operating income | 15.44B USD | 16.48B USD | 5.29B USD | 37.55B USD | 20.79B USD |
| Net income | 7.77B USD | 8.02B USD | 2.13B USD | 31.37B USD | 22.15B USD |
Company facts updated Sep 13, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$28.20
1.73% upsideCash distributions grouped by calendar year; partial years are marked.
$1.72
2025 complete year+10.3% since 2021
2026 partial: $1.29
$1.56
2,021
$1.60
2,022
$1.64
2,023
$1.68
2,024
$1.72
2,025
$1.29
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jul 24, 2026 | $0.43Quarterly | Jul 24, 2026 | Sep 1, 2026 |
Dividend | May 8, 2026 | $0.43Quarterly | May 8, 2026 | Jun 12, 2026 |
Dividend | Jan 23, 2026 | $0.43Quarterly | Jan 23, 2026 | Mar 6, 2026 |
Dividend | Nov 7, 2025 | $0.43Quarterly | Nov 7, 2025 | Dec 1, 2025 |
Dividend | Jul 25, 2025 | $0.43Quarterly | Jul 25, 2025 | Sep 2, 2025 |
Dividend | May 9, 2025 | $0.43Quarterly | May 9, 2025 | Jun 13, 2025 |
Ex-dividend Jul 24, 2026
$0.43
Quarterly
Record Jul 24, 2026 · Payment Sep 1, 2026
Ex-dividend May 8, 2026
$0.43
Quarterly
Record May 8, 2026 · Payment Jun 12, 2026
Ex-dividend Jan 23, 2026
$0.43
Quarterly
Record Jan 23, 2026 · Payment Mar 6, 2026
Ex-dividend Nov 7, 2025
$0.43
Quarterly
Record Nov 7, 2025 · Payment Dec 1, 2025
Ex-dividend Jul 25, 2025
$0.43
Quarterly
Record Jul 25, 2025 · Payment Sep 2, 2025
Ex-dividend May 9, 2025
$0.43
Quarterly
Record May 9, 2025 · Payment Jun 13, 2025
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI4.54B0.20%2.3T USD0.03%$376.31+0.82%
Vanguard S&P 500 ETFVOO3.74B0.22%1.7T USD0.03%$702.56+0.85%
iShares Core S&P 500 ETFIVV2.03B0.24%839.6B USD0.03%$767.92+0.84%
State Street SPDR S&P 500 ETFSPY1.92B0.24%799.37B USD0.09%$764.29+0.85%
Vanguard Morningstar Value ETFVTV1.36B0.53%256.5B USD0.03%$223.97+0.72%
State Street Health Care Select Sector SPDR ETFXLV1.13B2.64%42.99B USD0.08%$165.36-0.18%
iShares Core High Dividend ETFHDV719.01M4.68%15.35B USD0.08%$29.12+0.34%
Vanguard High Dividend Yield ETFVYM573.41M0.58%99.2B USD0.04%$162.92+0.67%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Value ETFVTV
State Street Health Care Select Sector SPDR ETFXLV
iShares Core High Dividend ETFHDV
Vanguard High Dividend Yield ETFVYMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.